Axon delivered a strong fourth quarter with revenue growing 39% year-over-year to $797 million, driven by robust demand for TASER 10 and software adoption. While the company reported a GAAP operating loss due to increased headcount and stock-based compensation, non-GAAP profitability remained strong with Adjusted EBITDA growing 46% year-over-year.

Axon posted another record quarter with $711 million in revenue, achieving its seventh consecutive quarter of 30%+ growth. While GAAP net income was slightly negative, non-GAAP results showed robust profitability. Software & Services led the growth with a 41% increase, and annual recurring revenue rose to $1.3 billion.

Axon delivered another record quarter with 33% revenue growth driven by strong adoption of premium software offerings and robust TASER 10 demand.

Axon reported strong Q1 2025 results with 31% year-over-year revenue growth led by software and services. Net income remained positive despite higher stock-based compensation, and the company raised its full-year revenue and EBITDA guidance.

Axon achieved record quarterly revenue of $575 million in Q4 2024, a 34% increase year-over-year. The company reported strong demand across key product segments, including TASER, Sensors & Other, and Axon Cloud & Services. Net income for the quarter reached $135 million, supported by non-GAAP net income of $169 million.

Axon reported a strong start to 2024, with Q1 revenue reaching $461 million, a 34% increase year-over-year. The company raised its full-year revenue outlook to $1.94 billion to $1.99 billion. Annual recurring revenue grew by 50% to $825 million, and net income was $133 million.

Axon's Q4 2023 revenue grew by 28.6% year over year, reaching $432 million, driven by strong demand across product categories. The company's net income was $57 million, or $0.75 per diluted share, while non-GAAP net income was $85 million, or $1.12 per diluted share. Axon Cloud software was the primary driver of revenue growth.

Axon reported strong Q3 2023 results with revenue up 33% year-over-year to $414 million. The company raised its full-year revenue outlook to approximately $1.55 billion, representing 30% annual growth, and expects a full-year Adjusted EBITDA margin just above 20%. Key growth drivers included Axon Cloud & Services, which increased 55% year-over-year, and the TASER segment, which grew 12% driven by the ramp of TASER 10.

Axon delivered a strong first half of 2023 with Q2 revenue growth of 31% year over year, driven by strength in Axon Cloud software, Axon Fleet and the initial ramp of our TASER 10 platform. The company achieved its sixth consecutive quarter of GAAP profitability and raised its full year revenue outlook to $1.51 billion to $1.53 billion.

Axon reported a strong start to 2023 with record quarterly revenue of $343 million, up 34% year over year, driven by strong demand for Axon Cloud SaaS services, Axon Fleet 3, and the TASER 7 platform. The company raised its full year outlook to 22% revenue growth and maintained its 20% Adjusted EBITDA margin.

Axon's Q4 2022 revenue grew above 50%, supported by financial discipline and fourth consecutive quarter of GAAP profitability. The company launched its moonshot goal and advanced its mission to protect life.

Axon reported a record Q3 2022 with revenue of $312 million, a 34% increase year-over-year. SaaS strength drove Axon Cloud revenue growth of 51%. The company raised its full-year outlook, expecting revenue between $1.15 billion and $1.16 billion and Adjusted EBITDA between $215 million and $220 million.

Axon reported record revenue of $286 million, a 31% increase year over year, driven by strong demand for its cloud SaaS solutions, body and fleet systems, and TASER platform. The company raised its full-year outlook and saw SaaS ARR increase by 41% to $368 million. Diluted EPS was $0.71 and non-GAAP diluted EPS was $0.44.

Axon reported a strong start to the year with Q1 2022 revenue up 32% to $256 million. The company raised its full year outlook, expecting 25% annual revenue growth. Net income was $55 million and Adjusted EBITDA was $49 million.

Axon's Q4 2021 revenue reached $218 million, a 4% year-over-year decrease, impacted by a large prior-year order and supply chain shifts. The company's full-year revenue grew by 27% to $863 million. Despite a quarterly net loss of $14 million, non-GAAP net income was $34 million, or $0.46 per share, and adjusted EBITDA was $31 million.

Axon reported strong Q3 2021 results, with record bookings of $488 million, up 54%. Revenue increased by 39% to $232 million, and GAAP net income was $49 million. The company also raised its 2022 revenue outlook to $1 billion.

Axon Enterprise reported a strong Q2 2021, with revenue up 55% year-over-year to $219 million. International revenue grew 60%, and the company raised its full-year outlook. The company's performance was driven by increasing global demand for its life-saving technology, including TASER devices and body cameras.

Axon Enterprise reported a strong start to 2021 with revenue growth of 33% year over year, driven by strong demand for TASER devices and software-heavy body camera bundles. The company is raising its full-year outlook.

Axon Enterprise reported a record $681 million in revenue for 2020, a 28% increase year-over-year, with Q4 2020 revenue growing 32% to $226 million. The company saw strong profitability and global demand for TASER devices, and raised its 2021 outlook.

Axon reported a strong Q3 2020, with revenue growth of 27% year-over-year. Annual recurring revenue (ARR) topped $200 million, and total bookings increased by 56% year-over-year. The company is on track to exceed its original 2020 financial targets.

Axon Enterprise reported a 26% year-over-year increase in revenue, reaching $141 million. International revenue grew by 80% year-over-year. Annual Recurring Revenue (ARR) also saw a significant increase of 42%. GAAP EPS was ($0.51) and Non-GAAP EPS was ($0.01).

Axon reported strong Q1 2020 results with revenue up 27% year-over-year. International revenue grew 38%, and the company saw increased adoption of its cloud software solutions. Axon is withdrawing its formal full year guidance due to COVID-19 but remains confident in its long-term outlook.

Axon's Q4 2019 revenue grew by 50% to $172 million, driven by demand for Axon Body 3, TASER 7, and cloud software. Adjusted EBITDA more than tripled to $38 million, representing a 22% margin.